Grundläggande statistik
| LEI | 213800CSKAC96ELS4K25 |
| CIK | 1321834 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MyMD Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 Q/C Techn |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-362 |
|
| April 15, 2026 |
EXECUTIVE COMPENSATION AGREEMENT Exhibit 10.34 EXECUTIVE COMPENSATION AGREEMENT This Executive Compensation Agreement (“Agreement”) is entered into as of April 13, 2026 (“Effective Date”), by and between Q/C Technologies, Inc., a Delaware corporation (together with its successors and assigns, the “Company”), and Josh Silverman (“Executive”). The Company and Executive are each referred to in this Agreement as a “Party” and collect |
|
| April 15, 2026 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHANGE ACT OF 1934, AS AMENDED This description of the capital stock of TNF Pharmaceuticals, Inc., a Delaware corporation (“we,” “our” and the “Company”) is intended as a summary and is qualified in its entirety by reference to our Certificate of Incorporation (the “Certificate of Incorporation”) and the Byl |
|
| April 15, 2026 |
Subsidiaries of the Registrant (as of December 31, 2025) Exhibit 21.1 Subsidiaries of the Registrant (as of December 31, 2025) Name of Company Jurisdiction of Organization Akers Acquisition Sub, Inc. New Jersey Bout Time Marketing Corporation New Jersey XYZ Merger Sub Inc. LPU Holdings LLC Florida Delaware |
|
| April 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 Q/C Technologies, |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| March 13, 2026 |
Exhibit 16.1 |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 Q/C Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 12, 2026 |
Q/C TECHNOLOGIES, INC. 1185 Avenue of the Americas New York, New York 10036 Q/C TECHNOLOGIES, INC. 1185 Avenue of the Americas New York, New York 10036 February 12, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Re: Q/C Technologies, Inc. Registration Statement on Form S-3 Filed on February 11, 2026 File No. 333-293394 (the “Registration Statement”) Request for Acceleration Ladies and G |
|
| February 11, 2026 |
Q/C TECHNOLOGIES, INC. [ ] Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Exhibit 4.20 Q/C TECHNOLOGIES, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5. |
|
| February 11, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 11, 2026 As filed with the U.S. Securities and Exchange Commission on February 11, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Q/C TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 22-2983783 (State or other jurisdiction of incorporation or organization) ( |
|
| February 11, 2026 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Q/C Technologies, Inc. |
|
| February 11, 2026 |
Q/C TECHNOLOGIES, INC. [ ] Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Exhibit 4.21 Q/C TECHNOLOGIES, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313 |
|
| January 28, 2026 |
January 28, 2026 Joshua Silverman Executive Chairman Q/C Technologies, Inc. 1185 Avenue of the Americas, Suite 249 New York, NY 10036 Re: Q/C Technologies, Inc. Draft Registration Statement on Form S-3 Submitted January 23, 2026 CIK No. 0001321834 Dear Joshua Silverman: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registr |
|
| January 23, 2026 |
Exhibit 10.1 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (the “Agreement”) is made effective as of January 16, 2026 (the “Effective Date”), by and between Q/C Technologies, Inc. (the “Company”) and Chelsea Voss (the “Consultant”) (collectively, the Company and the Consultant, shall be referred to as the “Parties” or individually as a “Party”). WHEREAS, the Consultant shall pro |
|
| January 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2026 Q/C Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission |
|
| January 23, 2026 |
Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors Exhibit 99.1 Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) — Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C Technologies” or “the Company”), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Chelsea Voss to its Board of Directors. Ms. Voss is a computer scientist and Member of Te |
|
| January 23, 2026 |
CONFIDENTIAL TREATMENT REQUESTED BY Q/C TECHNOLOGIES, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 As confidentially submitted to the Securities and Exchange Commission on January 23, 2026. This draft registration statement has not been publicly filed with the United States Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES |
|
| December 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2025 Q/C Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission |
|
| December 9, 2025 |
Exhibit 10.1 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (the “Agreement”) is made effective as of December 8, 2025 (the “Effective Date”), by and between Q/C Technologies, Inc. (the “Company”) and Ocean Avenue Holdings LLC (the “Consultant”) (collectively, the Company and the Consultant, shall be referred to as the “Parties” or individually as a “Party”). WHEREAS, the Consult |
|
| December 9, 2025 |
Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli Exhibit 99.1 Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli New York – December 9, 2025 – Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C” or “the Company”), a pioneer of quantum-class computing at the speed of light, today announced that Martin Shkreli become a Strategic Advisor to the Company, contributing his experience in technology, industry contacts, |
|
| December 9, 2025 |
Exhibit 4.1 FORM OF WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| December 1, 2025 |
Q/C Technologies, Inc. 6,511,799 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-290719 PROSPECTUS Q/C Technologies, Inc. 6,511,799 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to an aggregate of 6,511,799 shares of our common stock, par value $0.001 per share (the “Common Stock”), consisting of (i) 2,800,000 shares of Common Stock |
|
| November 25, 2025 |
Q/C Technologies, Inc. 1185 Avenue of the Americas New York, New York 10036 Q/C Technologies, Inc. 1185 Avenue of the Americas New York, New York 10036 November 25, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Jessica Dickerstein Re: Q/C Technologies, Inc. Registration Statement on Form S-3 Filed on October 3, 2025 File No. 333- 290719 (the “Registration Statement”) Request |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 Q/C T |
|
| November 14, 2025 |
SECOND AMENDMENT TO q/c technologies, Inc. 2021 Equity Incentive Plan Exhibit 10.1 SECOND AMENDMENT TO q/c technologies, Inc. 2021 Equity Incentive Plan This SECOND AMENDMENT TO Q/C TECHNOLOGIES, Inc. 2021 Equity Incentive Plan (this “Amendment”), effective as of November 14, 2025, is made and entered into by Q/C Technologies, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Q/C Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 Q/C Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of inco |
|
| October 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 Q/C Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi |
|
| October 3, 2025 |
Exhibit 10.1 OMNIBUS Waiver AND AMENDMENT This Omnibus Waiver and Amendment (this “Agreement”), dated as of September 30, 2025, is by and among Q/C Technologies, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated |
|
| October 3, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 Q/C Technologies, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| October 3, 2025 |
As Filed with the Securities and Exchange Commission on October 3, 2025 As Filed with the Securities and Exchange Commission on October 3, 2025 Registration No. |
|
| October 3, 2025 |
Exhibit 4.1 FORM OF WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| October 3, 2025 |
Exhibit 10.2 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (the “Agreement”) is made effective as October 1, 2025 (the “Effective Date”), by and between Q/C Technologies, Inc. (the “Company”), Z-List Media, Inc. (the “Consultant”), and James Altucher (the “Service Provider”) (collectively, the Company, the Consultant, and the Service Provider, the “Parties” or individually a “Pa |
|
| October 3, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF Q/C Technologies, Inc. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series H Convertible Preferred Stock (the “Amendment”) is dated as of October 3, 2025. WHEREAS, the board of directors (the “Board”) o |
|
| September 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2025 Q/C Technologies, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi |
|
| September 26, 2025 |
Exhibit 99.1 Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS” Licensed technology positions Company at forefront of new quantum-class computing paradigm New York, NY — Q/C Technologies, Inc. (Nasdaq: QCLS), formerly TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), (“Q/C” or “the Company”), today announced that its common stock will begin trading u |
|
| September 26, 2025 |
Certificate of Amendment Certificate of Incorporation TNF PHARMACEUTICALS, INC. Exhibit 3.1 Certificate of Amendment of Certificate of Incorporation of TNF PHARMACEUTICALS, INC. TNF Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) hereby certifies: 1. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware on October |
|
| September 26, 2025 |
Exhibit 99.2 TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing New trading symbol QCLS effective Thursday, September 25, 2025 Licensed technology positions Company at forefront of new quantum-class computing paradigm New York, NY — TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“Q/C” or the “Company” |
|
| September 18, 2025 |
September 18, 2025 Mitchell Glass President and Chief Medical Officer TNF Pharmaceuticals, Inc. |
|
| September 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis |
|
| September 10, 2025 |
Exhibit 99.1 TNF Pharmaceuticals Announces Closing of $7 Million Private Placement Financing priced at a 44% premium to market Led by a top strategic investor with significant participation from existing stockholders New York, NY — September 4, 2025 — TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced the closing of a $7.0 million private placement financing of conve |
|
| September 10, 2025 |
Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW This Second Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock (this “Amended and Restated Certificate of Designations”) is dated as of September 3, 2025 (the “E |
|
| September 10, 2025 |
CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. I, Joshua Silverman, hereby certify that I am the Executive Chairman of TNF Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferred |
|
| September 10, 2025 |
Exhibit 3.3 EXHIBIT I AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. This Amended and Restated Certificate of Designations of Series F-1 Convertible Preferred Stock (this “Amended and Restated Certificate of Designations”) is dated as of September 3, 2025 (the “Effective Date”); WHEREAS, the board of directors (the “Board”) o |
|
| September 10, 2025 |
Exhibit 3.4 TNF PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES I CONVERTIBLE PREFERRED STOCK I, Joshua Silverman, hereby certify that I am the Executive Chairman of TNF Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to |
|
| September 5, 2025 |
X0708 D LIVE 0001321834 TNF Pharmaceuticals, Inc. 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY NEW YORK 10036 856-848-8698 DELAWARE None MyMD Pharmaceuticals, Inc. Akers Biosciences, Inc. Akers Biosciences Inc Corporation true 2023 Ian Rhodes 1185 Avenue of the Americas Suite 249 New York NY NEW YORK 10036 Executive Officer Chief Financial Officer Christopher Schreiber 1185 Avenue of the Amer |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm |
|
| September 5, 2025 |
Exhibit 10.2 STOCKHOLDER VOTING AGREEMENT THIS STOCKHOLDER VOTING AGREEMENT (this “Agreement”) is made and entered into as of September 4, 2025, by and among TNF Pharmaecuticals, Inc. (the “Company”) and each of the undersigned Stockholders of the Company (the “Stockholders”). RECITALS A. WHEREAS, on September 2, 2025, the Stockholders and the Company entered into a Member Interest Purchase Agreem |
|
| September 5, 2025 |
TECHNOLOGY LICENSE AND DEVELOPMENT AGREEMENT Exhibit 10.4 TECHNOLOGY LICENSE AND DEVELOPMENT AGREEMENT This Technology License and Development Agreement (the “Agreement”) is made and entered into as of September 2, 2025 (subject to Section 10.1, the “Effective Date”), by and among LightSolver Ltd., an Israeli company with its principal place of business at Yigal Alon 94b, 14th floor, Tel Aviv, Israel (“LightSolver” or “LS”); and LPU Holdings |
|
| September 5, 2025 |
Exhibit 10.1 Execution Version Membership Interest Purchase Agreement by and between LPU HOLDINGS LLC (the “Company”) and TNF PHARMACEUTICALS, INC. (“Buyer”), with the Members of the Company joining solely for purposes of Article V Dated as of September 2, 2025 Membership Interest Purchase Agreement This Membership Interest Purchase Agreement (this “Agreement”), dated as of September 2, 2025, is e |
|
| September 5, 2025 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [ ], 2025 (the “Execution Date”), is entered into by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and LPU Holdings LLC (“LPU”) and the sellers (each, individually, a “Seller,” and collectively, “Sellers”) identified on the signature pages to that certain Me |
|
| September 2, 2025 |
Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. This Amended and Restated Certificate of Designations of Series F-1 Convertible Preferred Stock (this “Amended and Restated Certificate of Designations”) is dated as of [ ], 2025 (the “Effective Date”); WHEREAS, the board of directors (the “Board”) of TNF Pharmaceutic |
|
| September 2, 2025 |
CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. I, Joshua Silverman, hereby certify that I am the Executive Chairman of TNF Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferred |
|
| September 2, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 2, 2025, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company has authorized a new series of c |
|
| September 2, 2025 |
Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Second Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock (this “Amended and Restated Certificate of Designations”) is dated as of [ ], 2025 (the “Effective |
|
| September 2, 2025 |
TNF PHARMACEUTICALS, INC. Warrant To Purchase Common Stock Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| September 2, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 2, 2025, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of |
|
| September 2, 2025 |
TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance Exhibit 99.2 TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance New York, NY — August 28, 2025 — TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that its board of directors has authorized a reverse stock split |
|
| September 2, 2025 |
Exhibit 99.1 TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications First light- and laser-based computing system designed to outperform quantum and supercomputing and solve complex problems unfeasible for GPUs Strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gart |
|
| September 2, 2025 |
Exhibit 10.3 OMNIBUS Amendment AGREEMENT This Omnibus Amendment Agreement (this “Agreement”), dated as of September 2, 2025, is by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, date |
|
| September 2, 2025 |
CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION TNF Pharmaceuticals, Inc. Exhibit 3.4 CERTIFICATE OF AMENDMENT Of CERTIFICATE OF INCORPORATION OF TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The Certificate of Incorporation of the Corporation (as amended, the “Certificate of Incorporation”) was filed w |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 TNF Pharma |
|
| August 19, 2025 |
TNF Pharmaceuticals, Inc. 1185 Avenue of the Americas, Suite 249 New York, NY TNF Pharmaceuticals, Inc. 1185 Avenue of the Americas, Suite 249 New York, NY August 19, 2025 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Attention: Daniel Crawford and Jason Drory Re: TNF Pharmaceuticals, Inc. Annual Report on Form 10-K for fiscal year ended December 31, 2024 Originally filed on April 11, 2025 Fi |
|
| August 19, 2025 |
Certificate of Amendment of Certificate of Designations of Series F-1 Convertible Preferred Stock. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series F-1 Convertible Preferred Stock (the “Amendment”) is dated as of August 19, 2025. WHEREAS, the board of directors (the “Bo |
|
| August 19, 2025 |
Exhibit 10.1 OMNIBUS Amendment AGREEMENT This Omnibus Amendment Agreement (this “Agreement”), dated as of August 19, 2025, is by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated |
|
| August 19, 2025 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series F Convertible Preferred Stock (the “Amendment”) is dated as of August 19, 2025. WHEREAS, the board of directors (the “Board” |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| August 5, 2025 |
August 5, 2025 Mitchell Glass President and Chief Medical Officer TNF Pharmaceuticals, Inc. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2025 |
CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION TNF Pharmaceuticals, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT Of CERTIFICATE OF INCORPORATION OF TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is TNF Pharmaceuticals, Inc. 2. The Certificate of Incorporation of this Corporation |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 TNF Pharm |
|
| May 9, 2025 |
First Amendment to the Bylaws of TNF Pharmaceuticals, Inc. Exhibit 3.1 FIRST AMENDMENT TO THE BYLAWS OF TNF PHARMACEUTICALS, INC. Pursuant to Article VIII of the Certificate of Incorporation, as amended, of TNF Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), Article X of the Bylaws (the “Bylaws”) of the Corporation, and Section 109 of the General Corporation Law of the State of Delaware, on the date hereof, the Bylaws of the Corporation |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission F |
|
| April 21, 2025 |
TNF Pharmaceuticals, Inc. 2024 Annual Report to Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 11, 2025 |
TNF Pharmaceuticals, Inc. Insider Trading Policy. Exhibit 19.1 Insider Trading This statement sets forth the policies of TNF Pharmaceuticals on trading and causing the trading of securities while in possession of material non-public information. Sections 1 through 3 and Section 5 applies to all persons associated with the Corporation including consultants. The entire policy applies to the following “Covered Persons”: (i) all directors of the Corp |
|
| April 11, 2025 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio |
|
| April 11, 2025 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHANGE ACT OF 1934, AS AMENDED This description of the capital stock of TNF Pharmaceuticals, Inc., a Delaware corporation (“we,” “our” and the “Company”) is intended as a summary and is qualified in its entirety by reference to our Certificate of Incorporation (the “Certificate of Incorporation”) and the Byl |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 TNF Pharmaceutica |
|
| April 11, 2025 |
Exhibit 3.5.3 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series F Convertible Preferred Stock (the “Amendment”) is dated as of April 8, 2025. WHEREAS, the board of directors (the “Board” |
|
| April 11, 2025 |
Exhibit 10.45 OMNIBUS Amendment AGREEMENT This Omnibus Amendment Agreement (this “Agreement”), dated as of April 8, 2025, is by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated a |
|
| April 11, 2025 |
Certificate of Amendment of Certificate of Designations of Series F-1 Convertible Preferred Stock. Exhibit 3.6.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Certificate of Designations of Series F-1 Convertible Preferred Stock (the “Amendment”) is dated as of April 8, 2025. WHEREAS, the board of directors (the “Bo |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| March 21, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio |
|
| March 10, 2025 |
Transcript of Conference Call, held March 6, 2025. Exhibit 10.1 TNF Pharmaceuticals Investor Update Conference Call March 6, 2025 Presenters Mitchell Glass - Director, President and Chief Medical Officer Operator Good afternoon, everyone, and welcome to the TNF Pharmaceuticals Investor Conference call and Clinical Scientific Update. Today’s call will be conducted by the Company’s President and Chief Medical Officer, Dr. Mitchell Glass. Before I tu |
|
| March 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis |
|
| November 26, 2024 |
First Amendment to the TNF Pharmaceuticals, Inc. 2021 Equity Incentive Plan Exhibit 10.1 FIRST AMENDMENT TO TNF Pharmaceuticals, Inc. 2021 Equity Incentive Plan This FIRST AMENDMENT TO TNF Pharmaceuticals, Inc. 2021 Equity Incentive Plan (this “Amendment”), effective as of November 1, 2024, is made and entered into by TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not otherwise defined |
|
| November 14, 2024 |
TNFA / TNF Pharmaceuticals, Inc. / Global X Management CO LLC - SC 13G/A Passive Investment SC 13G/A 1 ef20038672sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION STATEMENT TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (b) (Amendment No. 1)* TNF Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62856X201 (CUS |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 TNF P |
|
| November 1, 2024 |
TNF Pharmaceuticals, Inc. 2023 Annual Report to Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ցց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 7, 2024 |
October 7, 2024 Mitchell Glass President and Chief Medical Officer TNF Pharmaceuticals, Inc. |
|
| October 7, 2024 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (“Agreement”) is made and entered into as of October 1, 2024 (“Effective Date”), between TNF Pharmaceuticals, Inc. (the “Company”) and Prevail Partners, LLC (“Prevail Partners”), Tax ID# 27-0256095. The Company and Prevail Partners are collectively referred to herein as the “Parties.” WITNESSETH WHEREAS, the Company identifies and |
|
| October 7, 2024 |
Exhibit 99.1 TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market Prevail Partners, LLC investment priced at 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of clinical trials over a decade TNF Pharmaceuticals fully funded for clinical trials for next two years BALTIMORE — Octob |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi |
|
| October 4, 2024 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi |
|
| October 4, 2024 |
Letter dated October 4, 2024 from Morison Cogen LLP to the U.S. Securities and Exchange Commission. Exhibit 16.1 October 4, 2024 Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Ladies and Gentlemen: We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on September 30, 2024, to be filed by our former client, TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.). We agree with the statements made in response to th |
|
| September 30, 2024 |
TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD September 30, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Attention: Doris Stacey Gama and Suzanne Hayes Re: TNF Pharmaceuticals, Inc. Annual Report on Form 10-K for fiscal year ended December 31, 2023 Originally filed on April 1, 2024 Fil |
|
| September 23, 2024 |
September 23, 2024 Mitchell Glass President and Chief Medical Officer TNF Pharmaceuticals, Inc. |
|
| September 23, 2024 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi |
|
| August 19, 2024 |
Form of Amendment to Series F-1 Long Term Warrant. Exhibit 4.6 Amendment This Amendment (this “Amendment”), dated as of August [ ], 2024, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 2024 (the “Purchase Agre |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 TNF Pharma |
|
| August 19, 2024 |
Form of Amendment to Series G Short Term Warrant. Exhibit 4.9 Amendment This Amendment (this “Amendment”), dated as of August [ ], 2024, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 2024 (the “Purchase Agre |
|
| August 19, 2024 |
Form of Amendment to Series G Long Term Warrant. Exhibit 4.8 Amendment This Amendment (this “Amendment”), dated as of August [ ], 2024, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 2024 (the “Purchase Agre |
|
| August 19, 2024 |
Form of Amendment to Series F-1 Short Term Warrant. Exhibit 4.7 Amendment This Amendment (this “Amendment”), dated as of August [ ], 2024, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 2024 (the “Purchase Agre |
|
| August 14, 2024 |
Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock. Exhibit 3.1 Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock of TNF PHARMACEUTICALS, INC. Pursuant to Section 242 of the Delaware General Corporation Law This Certificate of Amendment to the Certificate of Designations of Series G Convertible Preferred Stock (the “Amendment”) is dated as of August 8, 2024. WHEREAS, the board of directors (the “Board”) |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| August 14, 2024 |
Exhibit 10.1 Amendment AGREEMENT This Amendment Agreement (this “Agreement”), dated as of August 8, 2024, is by and between TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 202 |
|
| August 12, 2024 |
TNF Pharmaceuticals, Inc. 65,117,652 Shares of Common Stock (and up to 4,500,000 Dividend Shares) Filed Pursuant to Rule 424(b)(3) Registration No. 333-280415 PROSPECTUS TNF Pharmaceuticals, Inc. 65,117,652 Shares of Common Stock (and up to 4,500,000 Dividend Shares) This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to an aggregate of 69,617,652 shares of our common stock, par value $0.001 per share (the “Common Stock”), issuable |
|
| August 9, 2024 |
TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205 TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205 August 9, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Attention: Tamika Sheppard Re: TNF Pharmaceuticals, Inc. (f/k/a MyMD Pharmaceuticals, Inc.) Registration Statement on Form S-3 Originally filed on June 21, 2024, as amended on Aug |
|
| August 8, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 TNF Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| August 8, 2024 |
As Filed with the Securities and Exchange Commission on August 8, 2024 As Filed with the Securities and Exchange Commission on August 8, 2024 Registration No. |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission |
|
| July 26, 2024 |
Exhibit 99.1 MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies TNF Pharmaceuticals will begin trading on Nasdaq under the new trad |
|
| July 26, 2024 |
Exhibit 99.2 TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system BALTIMORE — July 24, 2024 — TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the “Company”), a cli |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 TNF Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission |
|
| July 26, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT Of CERTIFICATE OF INCORPORATION OF TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is TNF Pharmaceuticals, Inc. 2. The Certificate of Incorporation of this Corporation |
|
| July 26, 2024 |
Exhibit 3.1 Certificate of Amendment of Certificate of Incorporation of MYMD PHARMACEUTICALS, INC. MyMD Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) hereby certifies: 1. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware on Octob |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 27, 2024 |
United States securities and exchange commission logo June 27, 2024 Joshua Silverman Chairman of the Board MyMD Pharmaceuticals, Inc. |
|
| June 24, 2024 |
Exhibit 3.1 Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock of MyMD PHARMACEUTICALS, INC. Pursuant to Section 242 of the Delaware General Corporation Law This Certificate of Amendment to the Certificate of Designations of Series G Convertible Preferred Stock (the “Amendment”) is dated as of June 17, 2024. WHEREAS, the board of directors (the “Board”) |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio |
|
| June 21, 2024 |
As Filed with the Securities and Exchange Commission on June 21, 2024 As Filed with the Securities and Exchange Commission on June 21, 2024 Registration No. |
|
| June 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 MyMD Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry For |
|
| June 20, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorp |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 17, 2024 |
Exhibit 10.2 GENERAL RELEASE AND SEVERANCE AGREEMENT This General Release and Severance Agreement (the “Agreement”), dated as of June 14 2024 is made and entered into by and between Chris Chapman, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”). For good and valuable consideration, receipt of which is hereby acknowledged, in order to effect a mutually satisfactory and amicable sep |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio |
|
| June 17, 2024 |
Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock. Exhibit 3.1 Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock of MyMD PHARMACEUTICALS, INC. Pursuant to Section 242 of the Delaware General Corporation Law This Certificate of Amendment to the Certificate of Designations of Series G Convertible Preferred Stock (the “Amendment”) is dated as of June [ ], 2024. WHEREAS, the board of directors (the “Board” |
|
| June 17, 2024 |
Exhibit 10.1 Amendment AGREEMENT This Amendment Agreement (this “Agreement”), dated as of June 17, 2024, is by and between MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Purchase Agreement, dated as of May 20, 202 |
|
| June 17, 2024 |
Exhibit 99.1 MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer ● Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® ● Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of |
|
| May 30, 2024 |
MYMD / MyMD Pharmaceuticals, Inc. / PharmaCyte Biotech, Inc. - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. )* MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 62856X102 (CUSIP Number) Carlos Trujillo c/o PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, Nevada 89169 (917) 595-2850 (Name, |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission |
|
| May 23, 2024 |
Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES G CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Christopher Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferre |
|
| May 23, 2024 |
Exhibit 3.2 CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Christopher Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly confer |
|
| May 21, 2024 |
Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (the “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer is executing and deli |
|
| May 21, 2024 |
Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commission |
|
| May 21, 2024 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of May |
|
| May 21, 2024 |
Form of Certificate of Designations of Series F-1 Convertible Preferred Stock. Exhibit 3.2 CERTIFICATE OF DESIGNATIONS OF SERIES F-1 CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Christopher Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly confer |
|
| May 21, 2024 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of May |
|
| May 21, 2024 |
Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| May 21, 2024 |
Exhibit 4.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| May 21, 2024 |
Exhibit 3.3 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF MYMD PHARMACEUTICALS, INC. PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW This Certificate of Amendment to the Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock (the “Amendment”) is dated as of May 21, 2024. WHER |
|
| May 21, 2024 |
Exhibit 10.2 Securities Purchase Agreement This Securities Purchase Agreement (the “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer is executing and deli |
|
| May 21, 2024 |
Exhibit 4.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| May 21, 2024 |
Exhibit 10.5 Omnibus Waiver, Consent, Notice and Amendment This Omnibus Waiver, Consent and Amendment (this “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”). WITNESSETH Whereas, the Company and the Investor are party to that certain Securities Pu |
|
| May 21, 2024 |
Exhibit 99.1 MyMD Pharmaceuticals Secures Strategic Investments Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front BALTIMORE — May 21, 2024 — MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies f |
|
| May 21, 2024 |
Form of Certificate of Designations of Series G Convertible Preferred Stock. Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES G CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Christopher Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferre |
|
| May 15, 2024 |
Exhibit 4.1 Amendment This Amendment (this “Amendment”), dated as of [ ], 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the signature pages attached hereto (the “Investors”). WITNESSETH Whereas, the Company and the Investors are party to that certain Securities Purchase Agreement, dated as of February 21, 2023 (the “Pu |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36268 MyMD Phar |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi |
|
| April 8, 2024 |
Exhibit 3.1 Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock of MyMD Pharmaceuticals, Inc. Pursuant to Section 242 of the Delaware General Corporation Law This Amended and Restated Certificate of Designations of Series F Convertible Preferred Stock (this “Amended and Restated Certificate of Designations”) is dated as of April 5, 2024 (the “Effective Date”). |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio |
|
| April 8, 2024 |
Exhibit 10.1 Omnibus Waiver and Amendment This Omnibus Waiver and Amendment (this “Agreement”), dated as of April , 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the signature pages attached hereto (the “Investors”). WITNESSETH Whereas, the Company and the Investors are party to that certain Securities Purchase Agreeme |
|
| April 1, 2024 |
MyMD Pharmaceuticals, Inc. Compensation Recovery Policy Exhibit 97.1 MyMD Pharmaceuticals, Inc. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) of MyMD Pharmaceuticals, Inc. (the “Company”) is hereby adopted as of November 22, 2023 in compliance with Rule 5608 of the Nasdaq Rules. Certain terms used herein shall have the meanings set forth in “Section 3. Definitions” below. Section 1. Recovery Requirement Subject to Secti |
|
| April 1, 2024 |
Exhibit 10.58 SEVENTH AMENDMENT TO EMPLOYMENT AGREEMENT This SEVENTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of September 8, 2023 (the “Effective Date”), by and between Chris Chapman, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, amended on December 18, |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pharmaceutic |
|
| April 1, 2024 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHANGE ACT OF 1934 This description of the capital stock of MyMD Pharmaceuticals, Inc., a Delaware corporation (“we,” “our” and the “Company”) is intended as a summary and is qualified in its entirety by reference to our certificate of incorporation (the “Certificate of Incorporation”) and the by-laws (the “ |
|
| March 26, 2024 |
Exhibit 3.3 CERTIFICATE OF CORRECTION OF MyMD Pharmaceuticals, Inc., a Delaware corporation MyMD Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) hereby certifies: 1. The name of the Corporation is MyMD Pharmaceuticals, Inc. 2. The Certificate of Incorporation of the Corporation (the “Certifi |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incor |
|
| March 7, 2024 |
Exhibit 2.1 Agreement and Plan of Merger Between MyMD Pharmaceuticals, Inc., a New Jersey Corporation and MyMD Pharmaceuticals, Inc., a Delaware Corporation This Agreement and Plan of Merger (the “Agreement”), dated as of March 4, 2024, is made by and between MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), and MyMD Pharmaceuticals, Inc. (d/b/a MyMD Sub, Inc.), a Delaware corp |
|
| March 7, 2024 |
Exhibit 3.1 Certificate of Incorporation of MyMD Pharmaceuticals, Inc. ARTICLE I The name of the corporation is MyMD Pharmaceuticals, Inc. (hereinafter referred to as the “Corporation”). ARTICLE II The address of the Corporation’s registered office is Corporation Trust Center, 1209 Orange St., Wilmington, New Castle County, Delaware 19801. The name of the registered agent at such address is The Co |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio |
|
| March 7, 2024 |
Exhibit 3.2 BYLAWS OF MyMD Pharmaceuticals, Inc. A DELAWARE CORPORATION (Effective as of March 4, 2024) Table of Contents Table of Contents i Article I. Corporate Offices 1 Section 1.01 Registered Office. 1 Section 1.02 Other Offices. 1 Article II. Meetings of Stockholders 1 Section 2.01 Places of Meetings. 1 Section 2.02 Annual Meeting. 1 Section 2.03 Special Meeting 1 Section 2.04 Advance Notice |
|
| March 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissio |
|
| March 5, 2024 |
Exhibit 99.1 MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing BALTIMORE, MD – March 5, 2024 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced that it received |
|
| February 14, 2024 |
MYMD / MyMD Pharmaceuticals, Inc. / Iroquois Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 5)* MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 62856X102 (CUSIP Number) December 31, 2023 |
|
| February 14, 2024 |
SC 13G 1 annualsc13g-potxmymdpharma.htm ANNUAL SC 13G - POTX/MYMD PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION STATEMENT TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (b) MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Sec |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 MyMD Pharmaceuticals, Inc (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm |
|
| February 13, 2024 |
Exhibit 3.1 New Jersey Division of Revenue CERTIFICATE OF AMENDMENT to the AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (For Use by Domestic Profit Corporation) Pursuant to the provisions of Sections 14A:9-2(2), 14A:9-4(2), and 14A:7-15.1(3), Corporations, General, of the New Jersey Statutes, the undersigned corporation executes the following Certificate of Amendment to its Amended and Restat |
|
| February 13, 2024 |
Exhibit 99.1 MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024 BALTIMORE, MD – February 13, 2024 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and in |
|
| December 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm |
|
| December 6, 2023 |
Exhibit 99.1 MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis Company targets first quarter 2024 for trial initiation Potential to be first orally-administered TNF-α inhibitor treatment for RA BALTIMORE—December 6, 2023 (BUSINESS WIRE)— MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company com |
|
| November 14, 2023 |
Exhibit 10.4 EMPLOYMENT MUTUAL SEPARATION AGREEMENT THIS EMPLOYMENT MUTUAL SEPARATION AGREEMENT (this “Agreement”) is made and entered into as of the 13th day of November, 2023, by and between Paul M. Rivard, Esq. (“Employee”) and MyMD Pharmaceuticals, Inc. (“Company”). RECITALS: A. Pursuant to the Employment Agreement, dated September 21, 2020 and amended on November 24, 2020, December 18, 2020, |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pha |
|
| November 14, 2023 |
Exhibit 10.3 fourTH AMENDMENT TO EMPLOYMENT AGREEMENT This fourTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of November 13, 2023 (the “Effective Date”), by and between Adam Kaplin, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of December 18, 2020, amended on February 10, 2021 |
|
| November 14, 2023 |
Exhibit 10.5 fIRST AMENDMENT TO AGREEMENT This first AMENDMENT TO executive chairman AGREEMENT (this “Amendment”), is entered into as of November 13, 2023 (the “Effective Date”), by and between Christopher C. Schreiber (“Employee”) and MyMD Pharmaceuticals, Inc. (formerly known as Akers Biosciences, Inc.) (the “Company”), for the purpose of amending that certain Executive Chairman Agreement, dated |
|
| November 14, 2023 |
Exhibit 10.2 EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENT This EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of November 13, 2023 (the “Effective Date”), by and between Chris Chapman, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, amended on December 18, 202 |
|
| October 19, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm |
|
| October 19, 2023 |
Exhibit 99.1 MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain - Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours - Results suggest Supera-CBD may target specific pain pathways, lessening the potential for side effects - MyMD was issued Japanese Patent |
|
| October 13, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm |
|
| October 4, 2023 |
Exhibit 99.1 MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023 - Company to share new positive, statistically significant results across Cohort 4 (1050mg) from Phase 2 study of MYMD-1 in sarcopenia, an age-related frailty disorder - BALTIMORE, MD – October 4, 2023 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYM |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pharmace |
|
| August 14, 2023 |
Exhibit 99.1 FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA) - Next-generation and first oral TNF-α inhibitor, which completed Phase 2 study for age-related condition sarcopenia, represents a potentially groundbreaking advance in the treatment of RA and disruption of a $41 billion industry - |
|
| August 14, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commi |
|
| August 3, 2023 |
Transcript of MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Phase 2 Trial Update August 2, 2023 Exhibit 99.1 Transcript of MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Phase 2 Trial Update August 2, 2023 Participants Joshua Silverman - Chairman, MyMD Pharmaceuticals, Inc. Chris Chapman - President, Director, and Chief Medical Officer, MyMD Pharmaceuticals, Inc. Adam Kaplin - Chief Scientific Officer, MyMD Pharmaceuticals, Inc. Presentation Operator Good day everyone, and welcome to the My |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss |
|
| July 31, 2023 |
Exhibit 99.1 MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty - MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1 |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss |
|
| June 30, 2023 |
MyMD Pharmaceuticals, Inc. 2022 Annual Report to Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commissi |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pharmac |
|
| April 12, 2023 |
Corporate Presentation, dated April 2023 (furnished herewith pursuant to Item 7.01) Exhibit 99.2 |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis |
|
| April 12, 2023 |
Exhibit 99.1 MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan - Currently, there are no FDA-approved treatments for sarcopenia/frailty - - MyMD is only 3 patients away from dosing its final patient in its first Phase 2 clinical trial of lead drug candidate MYMD-1® - BALTIMORE, MD – April 12 |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36268 MyMD Pharmaceutic |
|
| March 31, 2023 |
List of Subsidiaries of MyMD Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of the Registrant1 Name of Company Jurisdiction of Organization Akers Acquisition Sub, Inc. New Jersey Bout Time Marketing Corporation New Jersey XYZ Merger Sub Inc. Florida 1 This information is as of March 29, 2023. |
|
| March 31, 2023 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHANGE ACT OF 1934 This description of the capital stock of MyMD Pharmaceuticals, Inc., a New Jersey corporation (“we,” “our” and the “Company”) is intended as a summary and is qualified in its entirety by reference to our amended and restated certificate of incorporation, as amended (the “Amended and Restat |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis |
|
| March 23, 2023 |
Exhibit 10.1 Third AMENDMENT TO EMPLOYMENT AGREEMENT This third AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of March 22, 2023 (the “Effective Date”), by and between Paul Rivard, Esq. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of September 21, 2020, and amended on November 24, 2020 |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commis |
|
| March 20, 2023 |
Exhibit 99.1 MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis Preclinical results showed MYMD-1® significantly reduced histopathological changes and the severity of standard arthritis clinical trial measures compared to placebo; demonstrate future potential to disrupt the TNF-α inhibitor market BALTIMORE, MD– Ma |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 8, 2023 |
MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls Exhibit 99.1 MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls BALTIMORE, MD – March 8, 2023 — MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that it has joined |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Commiss |
|
| March 2, 2023 |
Exhibit 99.1 MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical — DEA scientific review concludes Supera-CBD will not be classified as a regulated chemical or require scheduling during development — BALTIMORE, MD – March 2, 2023 — MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage bio |
|
| February 28, 2023 |
Exhibit 99.1 MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting — Study results comparing the anti-inflammatory effects of MYMD-1® to Enbrel (etanercept) accepted for poster presentation — BALTIMORE, MD– February 28, 2023 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com |
|
| February 23, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-254698 Prospectus Supplement (To prospectus dated May 11, 2021) MyMD Pharmaceuticals, Inc. 15,000 Shares of Preferred Stock 6,651,885 Warrants to purchase an aggregate of 6,651,885 Shares of Common Stock (and the Shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such Warrants) We are offering 15,000 sha |
|
| February 21, 2023 |
MyMD Announces $15 Million Offering with Existing Investors Exhibit 99.1 MyMD Announces $15 Million Offering with Existing Investors BALTIMORE—February 21, 2023—MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that it has executed a securities purchase agreeme |
|
| February 21, 2023 |
Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (the “Agreement”), dated as of , 2023, is by and among MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company has authorized, subject to acceptance of |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com |
|
| February 21, 2023 |
Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK OF MyMD PHARMACEUTICALS, INC. I, Chris Chapman, M.D., hereby certify that I am the President of MyMD Pharmaceuticals, Inc. (the “Company”), a corporation organized and existing under the New Jersey Business Corporation Act (the “BCA”), and further do hereby certify: That pursuant to the authority expressly conferred up |
|
| February 21, 2023 |
Exhibit 4.1 Form of Warrant MyMD Pharmaceuticals, Inc. Warrant To Purchase Common Stock Warrant No.: Date of Issuance: [●], 2023 (“Issuance Date”) MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, , the registered holder hereof or its permitted assigns (the |
|
| February 21, 2023 |
Exhibit 10.2 KATALYST SECURITIES LLC 630 THIRD AVENUE, 5TH FLOOR NEW YORK, NY 10017 TEL: 212-400-6993 FAX: 212-247-1059 Member: FINRA & SIPC February 21, 2023 STRICTLY CONFIDENTIAL MyMD Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 601 Baltimore, MD 21205 Ladies and Gentlemen: This letter (the “Agreement”) constitutes our understanding with respect to the engagement of Katalyst Securities LLC ( |
|
| February 14, 2023 |
MYMD / MyMD Pharmaceuticals, Inc. / Iroquois Capital Management, LLC Passive Investment SC 13G/A 1 c105644sch13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 4)* MyMD Pharmaceuticals, Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 62856X102 (C |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm |
|
| February 3, 2023 |
Exhibit 10.1 SIXTH AMENDMENT TO EMPLOYMENT AGREEMENT This sixth AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of January 1, 2023 (the “Effective Date”), by and between Chris Chapman, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, and as amended on December 18, |
|
| December 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Comm |
|
| December 8, 2022 |
Exhibit 99.1 MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022 - Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor, suggest future potential to disrupt the Rheumatoid Arthritis market - BALTIMORE, MD – December 6, 2022 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD |
|
| November 18, 2022 |
Exhibit 99.1 MyMD Pharmaceuticals? Announces Upcoming Presentation of Late-Breaking Data for MYMD-1? at the 2022 British Society for Immunology (BSI) Congress - Preclinical and early clinical studies of MYMD-1?, an oral, small-molecule, selective TNF-? inhibitor accepted for presentation - BALTIMORE, MD ? November 17, 2022 ? MyMD Pharmaceuticals, Inc.? (Nasdaq: MYMD) (?MyMD? or ?the Company?), a c |
|
| November 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com |
|
| November 14, 2022 |
Exhibit 99.1 MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research MYMD-1 demonstrated favorable safety and tolerability profile across multiple doses, with no clinically relevant adverse events, supporting advancement of the compound for Sarcopenia and Rheumatoid Arthritis BALTIMORE, MD. – November 14, 2022 – MyMD Ph |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 MyMD Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) New Jersey 001-36268 22-2983783 (State or other jurisdiction of incorporation) (Com |
